SEARCH

SEARCH BY CITATION

References

  • 1
    Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uremic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001; 14: 43754.
  • 2
    Sadler JE. A new name in thrombosis, ADAMTS13. Proc Natl Acad Sci USA 2002; 99: 115524.
  • 3
    Tsai HM. Deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 2003; 23: 38896.
  • 4
    Fujimura Y, Matsumoto M, Yagi H, Yoshioka A, Matsui T, Titani K. von Willebrand factor-cleaving protease and Upshaw–Schulman syndrome. Int J Hematol 2002; 75: 2534.
  • 5
    Moake JL. Mechanisms of disease—thrombotic microangiopathies. N Engl J Med 2002; 347: 589600.
  • 6
    Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 422334.
  • 7
    Tsaï HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 423544.
  • 8
    Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic–uremic syndrome. N Engl J Med 1998; 339: 157884.
  • 9
    Tsaï HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 158594.
  • 10
    Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloprotease family. Blood 2001; 98: 16626.
  • 11
    Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 4105963.
  • 12
    Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001; 98: 165461.
  • 13
    Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarod R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsaï HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 48894.
  • 14
    Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, Tamai H, Konno M, Kamide K, Kwano Y, Miyata T, Fujimura Y. Mutations and common polymorphisms in ADAMTS 13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002; 99: 119027.
  • 15
    Motto D, Levy G, McBee B, Tsai HM, Ginsburg D. ADAMTS13 mutations identified in familial TTP patients result in loss of von Willebrand factor-cleaving protease activity. Blood 2002; 100: 15a (Abstract).
  • 16
    Kentouche K, Budde U, Furlan M, Scharfe V, Schneppenheim R, Zintl F. Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma. Acta Paediatr 2002; 91: 10569.
  • 17
    Antoine G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt JD, Lämmle B, Scheiflinger F. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol 2003; 120: 8214.
  • 18
    Schneppenheim R, Budde U, Oyen E, Angerhaus D, Aumann V, Drewke E, Hassenpflug WA, Haberle J, Kentouche K, Kohne E, Kurnik K, Mueller-Wiefel DE, Obser T, Santer R, Sykora KW. Von Willebrand factor-cleaving protease and ADAMTS 13 mutations in childhood TTP. Blood 2003; 101: 184550.
  • 19
    Assink K, Schiphorst R, Allford S, Karpman D, Etzioni A, Brichard B, Van De Kar N, Monnens L, Van Den Heuvel L. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 2003; 63: 19959.
  • 20
    Savasan S, Lee SK, Ginsburg D, Tsai HM. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood 2003; 101: 444951.
  • 21
    Matsumoto M, Kokame K, Soejima K, Miura M, Hayashi S, Fujii Y, Iwai A, Ito E, Tsuji Y, Takeda-Shitaka M, Iwadate M, Umeyama H, Yagi H, Ishizashi H, Banno F, Nakagaki T, Miyata T, Fujimura Y. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw–Schulman syndrome. Blood 2003; prepublished on line October 16.
  • 22
    Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN, Hogg PJ. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood 2003; prepublished on line September 25.
  • 23
    Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 176572.
  • 24
    Veyradier A, Obert B, Haddad E, Cloarec S, Nivet H, Foulard M, Lesure L, Lahkadari M, Meyer D, Girma JP, Loirat C. Severe deficiency of specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. J Pediatrics 2003; 142: 3107.
  • 25
    Deschenes G, Veyradier A, Cloarec S, Benoit S, Desbois I, Gruel Y, Nivet H. Plasma therapy in von Willebrand factor protease deficiency. Pediatr Nephrol 2002; 17: 86770.
  • 26
    Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 1999; 82: 13825.
  • 27
    Zheng X, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem 2003; 278: 3013641.
  • 28
    Soejima K, Matsumoto M, Kokame K, Yagi H, Ishizashi H, Maeda H, Nozaki C, Miyata T, Fujimura Y, Nakagaki T. ADAMTS13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 2003; 102: 32327.
  • 29
    Bernardo A, Nolasco L, Ball C, Wang Y, Moake J, López J, Dong JF. Peptides from the C-terminal regions of ADAMTS-13 specifically block cleavage of ultra-large von Willebrand factor multimers on the endothelial surface under flow. J Thomb Haemost 2003; Suppl. 1, Abstract OC 405.